Vaccine damage: BioNTech in court in Hamburg
While Biontech announces that it will sponsor the Mainz 05 football club in future, the company is in the dock in Hamburg. For the first time, because of the Covid mRNA substance.
Source: Thomas Oysmüller, TKP.at, 17 September 2024
After Rheinmetall, which sponsors Borussia Dortmund, BioNTech is also entering the football business. In the future, the company will financially support the Bundesliga club Mainz 05, which is also the city in which BioNTech is based. The company is currently in court in Hamburg – a judgement against the pharmaceutical company could lead to a wave of lawsuits. A doctor is suing BioNTech for her vaccination injury.
Groundbreaking trial
The trial was due to start on Monday, but was apparently cancelled at short notice. The plaintiff, a doctor, is suing BioNTech for 150,000 euros in damages. She is one of many people affected by the vaccine: Since the vaccination, she has suffered from pain in her upper body, swelling of her extremities, exhaustion, fatigue and sleep disorders.
The trial is explosive, and the judgement will point the way forward. For BioNTech, it is the first trial in Germany concerning the Covid mRNA vaccine Comirnaty. If the plaintiff wins, this could open up the prospect of compensation for many other vaccine victims. However, if it loses, the Mainz-based company will probably breathe a sigh of relief.
Of course, BioNTech denies the allegations. The start of the trial was then postponed last week without giving any reasons. It should actually have taken place on Monday at 10 am. A new date has not been set.
In 2023, around 200 lawsuits were filed in Germany due to possible vaccine damage. Various vaccine manufacturers were sued. Astra Zeneca has already suffered a defeat: The company must hand over internal data as part of the lawsuit – TKP reported. As such a lawsuit represents an enormous amount of time and money, only very few vaccine victims actually have the chance to go to court. Judgements against the vaccine manufacturers could set further victims in motion.
The question of liability is also open: it cannot be ruled out that the contract between the EU Commission and BioNTech means that the state rather than the company will be liable for the damage. However, this would also first require a guilty verdict against the manufacturer.
Meanwhile, things are going well again on the stock market. In the last month, BioNTech shares have risen by 40 per cent. After the poor share prices in the summer, things are currently on the up again.
